Center-Authored Papers

Browse: Authors | Keywords | All Center-Authored Publications
Filter by Division: Basic | Clinical | Human Biology | PHS | VIDD (2010-present) | VIDI (2008-2009)
Filter by Year: 2008 | 2009 | 2010 | 2011 | 2012 | 2013

Filters: Author is Green, Damian J  [Clear All Filters]
B
Budde, LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
G
Green, DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur SD, Fisher DR, Rajendran JG et al..  2009.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.. Blood. 114(6):1226-35. Abstract
N
Nemecek, ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur SD, Nilsson R et al..  2008.  Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.. Cancer biotherapy & radiopharmaceuticals. 23(2):181-91. Abstract
O
Orozco, JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur SD, Fisher DR, Frayo SL, Hylarides MD, Green DJ et al..  2013.  Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.. Blood. Abstract
P
Pagel, JM, Hedin N, Drouet L, Wood BL, Pantelias A, Lin Y, Hamlin DK, Wilbur SD, Gopal AK, Green DJ et al..  2008.  Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.. Blood. 111(4):2261-8. Abstract
Pagel, JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
Pagel, JM, Orgun N, Hamlin DK, Wilbur SD, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW.  2009.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.. Blood. 113(20):4903-13. Abstract
Park, SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur SD, Stayton PS, Orgun N, Hylarides M, Buchegger F et al..  2011.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82. Abstract
Park, SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract